News
CRSP
56.16
+1.08%
0.60
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
NASDAQ · 2d ago
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
NASDAQ · 2d ago
First Week of CRSP May 31st Options Trading
NASDAQ · 2d ago
TD Cowen says sickle cell therapies may get higher CMS payments
Healthcare TD Cowen says sickle cell therapies may get higher CMS payments. Vertex/CRISPR’s Casgevy and bluebird bio's Lyfgenia were approved by the FDA for sicklecell disease in December. The two new therapies for the disease may get enhanced payments under proposed guidelines by CMS.
Seeking Alpha · 3d ago
Weekly Report: what happened at CRSP last week (0408-0412)?
Weekly Report · 3d ago
Portfolio Review: The Cat, The Tortoise And Me
Mauro Solis Vazquez Mellado created three portfolios inspired by animal archetypes. The Cat, The Tortoise and Me portfolios delivered a 22.4% return from March to the end of the year. The three portfolios were created to help investors understand the investment process.
Seeking Alpha · 4d ago
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
NASDAQ · 6d ago
Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune
Vertex Pharmaceuticals announced a $4.9 billion deal to buy Alpine Immune Sciences. The company is developing a drug to treat a rare kidney disease. Vertex is known for its treatment of cystic fibrosis. The deal is a big bet on the company's potential to diversify its business.
Barron‘s · 04/11 14:46
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $90 Price Target
Benzinga · 04/11 10:38
Crispr Therapeutics AG: A Buy Rating Backed by Innovative Gene-Editing Prospects and Strategic Growth
TipRanks · 04/11 10:05
Weekly Report: what happened at CRSP last week (0401-0405)?
Weekly Report · 04/08 10:07
Oversold Conditions For CRISPR Therapeutics (CRSP)
NASDAQ · 04/05 16:01
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
NASDAQ · 04/04 22:15
Buy Rating Affirmed for Crispr Therapeutics AG on Promising Gene Editing Developments and Expanding Treatment Pipeline
TipRanks · 04/03 05:46
Biotech Roundtable: Who will bring the next CRISPR drug to market?
Healthcare Biotech Roundtable: Who will bring the next CRISPR drug to market? CRisPR gene editing technology has been heralded as a revolutionary breakthrough in drug development. Last fall, the FDA approved the first CRISpr product for the US market. Seeking Alpha asked three analysts to weigh in on the technology and companies working in it.
Seeking Alpha · 04/02 15:36
Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development
NASDAQ · 04/02 15:26
Weekly Report: what happened at CRSP last week (0325-0329)?
Weekly Report · 04/01 10:06
Are Investors Vastly Underestimating CRISPR Therapeutics Stock (NASDAQ:CRSP)?
CRISPR Therapeutics (NASDAQ:CRSP) gained its second U.S. Regulatory approval for its CASGEVY program in January. The gene editing therapy was developed for the treatment of sickle-cell disease. The company has the potential to be a huge player in the field of gene editing.
TipRanks · 04/01 02:29
Is Beam Therapeutics Stock (NASDAQ:BEAM) Too Late to the Game?
TipRanks · 03/30 19:48
Crispr Therapeutics: Upcoming Catalysts May Validate The Bull Thesis And Force A Change In Plans
CRISPR Therapeutics has a diverse pipeline of gene therapies and strategic partnerships. The approval of CASGEVY, the first CRISPR-based medicine, signifies a significant milestone for the company. The company has upcoming catalysts that could validate the bull thesis. CRISpr Therapeutic is the first company to receive approval for a gene editing product.
Seeking Alpha · 03/30 07:03
More
Webull provides a variety of real-time CRSP stock news. You can receive the latest news about Crispr Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.